- Home
- GGG vs NBIX Comparison
GGG vs NBIX Comparison
Compare GGG & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGG
- NBIX
- Stock Information
- Founded
- GGG 1926
- NBIX 1992
- Country
- GGG United States
- NBIX United States
- Employees
- GGG N/A
- NBIX N/A
- Industry
- GGG Fluid Controls
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GGG Industrials
- NBIX Health Care
- Exchange
- GGG Nasdaq
- NBIX Nasdaq
- Market Cap
- GGG 14.1B
- NBIX 14.1B
- IPO Year
- GGG N/A
- NBIX 1996
- Fundamental
- Price
- GGG $84.77
- NBIX $140.44
- Analyst Decision
- GGG Hold
- NBIX Strong Buy
- Analyst Count
- GGG 3
- NBIX 18
- Target Price
- GGG $89.00
- NBIX $161.50
- AVG Volume (30 Days)
- GGG 592.1K
- NBIX 713.3K
- Earning Date
- GGG 10-22-2025
- NBIX 10-29-2025
- Dividend Yield
- GGG 1.30%
- NBIX N/A
- EPS Growth
- GGG N/A
- NBIX 2.97
- EPS
- GGG 2.82
- NBIX 3.39
- Revenue
- GGG $2,167,974,000.00
- NBIX $2,509,900,000.00
- Revenue This Year
- GGG $7.32
- NBIX $20.66
- Revenue Next Year
- GGG $4.19
- NBIX $14.64
- P/E Ratio
- GGG $30.07
- NBIX $41.44
- Revenue Growth
- GGG 0.75
- NBIX 18.42
- 52 Week Low
- GGG $72.06
- NBIX $84.23
- 52 Week High
- GGG $92.86
- NBIX $154.61
- Technical
- Relative Strength Index (RSI)
- GGG 47.22
- NBIX 55.60
- Support Level
- GGG $84.36
- NBIX $140.56
- Resistance Level
- GGG $86.19
- NBIX $144.04
- Average True Range (ATR)
- GGG 1.23
- NBIX 3.68
- MACD
- GGG -0.12
- NBIX -0.00
- Stochastic Oscillator
- GGG 26.15
- NBIX 56.04
About GGG Graco Inc.
Graco manufactures equipment used for managing fluids, coatings, and adhesives, specializing in difficult-to-handle materials. Graco's business is organized into three segments: industrial, process, and contractor. The Minnesota-based firm serves a wide range of end markets, including industrial, automotive, and construction, and its broad array of products include pumps, valves, meters, sprayers, and equipment used to apply coatings, sealants, and adhesives. The firm generated roughly $2.1 billion in sales in 2024.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.